MedTrace Logo

Influence of the Proton Pump Inhibitor Omeprazole on the Anti-Platelet of P2Y12 Antagonists in Subjects With Coronary and Peripheral Artery Disease

NCT01018940 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2014-12-04

No results posted yet for this study

Summary

To determine if prasugrel is superior to clopidogrel in providing adequate antiplatelet effect in a high risk population that requires concomitant use of a Proton Pump Inhibitor (PPI).

Conditions

Sponsors & Collaborators

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • Jorge Saucedo, MD · Dept of Cardiology

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01018940 on ClinicalTrials.gov